← Clinician redesign  /  Roster  ·  Dashboard  ·  Schedule  ·  Patient

Patient record, re-cut

LUKE · clinician surface · synthetic data

Reading one patient, two ways. The current build has no unified staff chart, so Before shows the conventional pattern this card system produces: a header, tabs, and stacked cards where the clinical signal is one row among many. After generalizes the AIPatientBriefPage dossier already in the repo: an edited clinical narrative with the decision pulled out, structured facts in a sidecar, and the one abnormal value impossible to miss. Patient invented.

BeforeConventional chart. Tabs and stacked cards. The story is buried in the data.
L
LUKEhealth
dr.okafor@clinic · physician

Marcus Reyes

MRN 4471 · 54 yo male · Patient since Oct 2025

OverviewMedicationsLabsMessagesOrdersNotes

Demographics

Age / Sex54 / Male
JoinedOct 21, 2025
Last visitMay 26, 2026
Care teamDr. Okafor

Active Medications (2)

Testosterone cypionate200mg / 2wk
Anastrozole0.5mg 2×/wk

Recent Labs (May 26)

Total testosterone612 ng/dL
Estradiol38 pg/mL
Hematocrit54%
PSA1.1 ng/mL

Allergies

Known allergiesNone on file
AfterHayman editorial. A dossier: the clinical narrative leads, the decision is pulled out, the abnormal value can't be missed.
L
LUKE
Dr. Okafor · Physician
The Patient/MRN 4471 · brief refreshed 2d ago

Marcus Reyes

54 · male · with you since Oct 2025 · testosterone replacement

Hematocrit 54% · high 8-week labs unreviewed
The brief

Marcus began testosterone cypionate, 200mg every two weeks, eight weeks ago for symptomatic hypogonadism, low energy, low libido, and a confirmed morning total testosterone of 210. He has tolerated therapy well and reports his symptoms are markedly improved. Anastrozole was added at week three to hold estradiol in range, which it has.

His eight-week follow-up panel resulted two days ago and has not yet been reviewed. Total testosterone is now mid-range at 612 and estradiol is controlled at 38. The concern is hematocrit, which has climbed to 54%, above the 52% threshold where erythrocytosis becomes a clotting risk on testosterone therapy. PSA is unremarkable at 1.1.

The decision in front of youHold or reduce the cypionate dose, lengthen the interval, or refer for a one-time therapeutic phlebotomy, then recheck hematocrit in four weeks. He has no reply owed and no visit booked.

No known drug allergies. Last seen by telehealth on 26 May; next visit is unscheduled.

Reading the difference. Before, the abnormal hematocrit is one red number in a four-card grid, carrying the same weight as the patient's join date. After, it is a flag in the masthead and a pulled-out decision, the brief tells you what is happening and what to do, and the structured facts sit in the sidecar for reference rather than being the whole page.
Guardrail honored: editorial claret (kickers, links, the drop cap) stays distinct from clinical-alert red (the abnormal value and the flags), so the magazine accent is never mistaken for a danger state.